Compare CRL & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRL | PRAX |
|---|---|---|
| Founded | 1947 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 9.0B |
| IPO Year | 1999 | 2020 |
| Metric | CRL | PRAX |
|---|---|---|
| Price | $161.25 | $344.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 15 |
| Target Price | $198.27 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 790.6K | 332.8K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,857,601,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.04 | $7,758.26 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.48 | N/A |
| 52 Week Low | $132.58 | $35.21 |
| 52 Week High | $228.88 | $358.76 |
| Indicator | CRL | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 55.46 |
| Support Level | $147.22 | $282.49 |
| Resistance Level | $166.62 | $353.86 |
| Average True Range (ATR) | 8.97 | 20.50 |
| MACD | -1.18 | 0.17 |
| Stochastic Oscillator | 31.12 | 71.68 |
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.